Business
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee. Following the appointment, the Board will be composed of 10 directors. “We are absolutely delighted to welcome Neha to the Arcutis Board,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “Neha brings incredible depth of business, financial, and investment experience, and has deep understanding of our business, having worked on our initial public offering in a previous role. She will be a wonderful addition to our board and will support the next stage of Arcutis’ growth. I am incredibly proud of the caliber and diversity of our entire Board of Directors, and look forward to working with Neha again as we bring meaningful innovation to medical dermatology.” “I am honored to join the Arcutis board at this pivotal time following the recent commercialization of ZORYVE™ (roflumilast) cream in plaque psoriasis, an important new treatment option for adults and adolescents,” said Neha Krishnamohan. “Ever since working on the Arcutis IPO, I have been impressed with not only the Company’s robust dermatological development pipeline and track record of executional success, but also the commitment of both the leadership and greater organization to solving unmet needs for individuals with immune-mediated skin diseases.” Ms. Krishnamohan is currently the Chief Financial Officer and Executive Vice President of Corporate Development at Kinnate Biopharma, with over 12 years of experience in healthcare investment banking and finance. Previously, Ms. Krishnamohan was the vice president in the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking Division at Goldman Sachs. While at Goldman Sachs, she established herself as a senior leader in the healthcare coverage group, working with a variety of biopharmaceutical boards and management teams on a broad range of strategic financial matters, executing financings as well as leading M&A transactions. Of note, she was one of the lead bankers on Arcutis’ highly successful 2020 initia...